Technical Analysis for SUPN - Supernus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 30.54 2.38% 0.71
SUPN closed up 2.38 percent on Friday, May 14, 2021, on 74 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical SUPN trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Multiple of Ten Bullish Other 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Outside Day Range Expansion 2.38%
Up 3 Days in a Row Strength 2.38%
Strong but Oversold Other 3.77%
Oversold Stochastic Weakness 3.77%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.95%
Lower Bollinger Band Touch Weakness 3.95%
Older End-of-Day Signals for SUPN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Supernus Pharmaceuticals, Inc. Description

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing products for the treatment of central nervous system diseases. Its products include SPN-538, an extended release topiramate product that completed clinical trials in support of new drug application for the treatment of epilepsy; Epliga, an extended release oxcarbazepine, which is in Phase III clinical trials targeting epilepsy; SPN-810, a molindone hydrochloride that is in Phase II clinical trials for treatment for impulsive aggression in patients with attention deficit hyperactivity disorder; and SPN-812, a Phase II clinical trial product targeting attention deficit hyperactivity disorder. The company also develops SPN-809, which has an open investigational new drug application for the treatment of depression. It intends to market its products to specialty physicians, including neurologists and psychiatrists in the United States. The company was founded in 2005 and is based in Rockville, Maryland.


Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Industry Drug Discovery Clinical Research Clinical Trial Chloride Neurology Epilepsy Depression Attention Deficit Attention Deficit Hyperactivity Disorder Clinical Trial Product Central Nervous System Disease Hyperactivity Disorder Central Nervous System Diseases Investigational New Drug Treatment Of Central Nervous System Diseases Treatment Of Depression Treatment Of Epilepsy

Is SUPN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 32.31
52 Week Low 17.2
Average Volume 528,631
200-Day Moving Average 24.99
50-Day Moving Average 28.65
20-Day Moving Average 30.58
10-Day Moving Average 29.88
Average True Range 1.09
ADX 18.75
+DI 19.19
-DI 19.69
Chandelier Exit (Long, 3 ATRs ) 29.05
Chandelier Exit (Short, 3 ATRs ) 31.88
Upper Bollinger Band 32.36
Lower Bollinger Band 28.80
Percent B (%b) 0.49
BandWidth 11.63
MACD Line 0.14
MACD Signal Line 0.35
MACD Histogram -0.2074
Fundamentals Value
Market Cap 1.61 Billion
Num Shares 52.7 Million
EPS 2.41
Price-to-Earnings (P/E) Ratio 12.67
Price-to-Sales 2.45
Price-to-Book 1.62
PEG Ratio 1.47
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.30
Resistance 3 (R3) 32.13 31.37 32.00
Resistance 2 (R2) 31.37 30.93 31.46 31.90
Resistance 1 (R1) 30.96 30.65 31.17 31.13 31.81
Pivot Point 30.20 30.20 30.31 30.29 30.20
Support 1 (S1) 29.79 29.76 30.00 29.96 29.27
Support 2 (S2) 29.03 29.48 29.12 29.18
Support 3 (S3) 28.62 29.03 29.08
Support 4 (S4) 28.79